Qurient KRX:115180KOSDAQ
큐리언트 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days12
DART filings, 7 days0
Articles tracked97since Sep 11
In Q2 2026, Qurient reported revenue of ₩1.9bn, up 3.4% year on year, and an operating loss of ₩12.8bn. Qurient (큐리언트) appeared in 12 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 19 with 12 articles. The most common catalyst was clinical & approvals (12). It was most often mentioned alongside Vaxcell-Bio Therapeutics.
Filing signals 4 quarters of losses Screener
Qurient quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.9bn | +3.4% | −₩12.8bn | −₩13.2bn |
| Q1 2026 | ₩1.9bn | +1.1% | −₩7.7bn | −₩7.9bn |
| Q4 2025 derived | ₩1.5bn | -45.8% | −₩9.3bn | −₩12.1bn |
| Q3 2025 | ₩1.7bn | -25.3% | −₩7.0bn | −₩6.6bn |
| Q2 2025 | ₩1.8bn | -7.0% | −₩6.8bn | −₩6.4bn |
| Q1 2025 | ₩1.9bn | -9.1% | −₩6.7bn | −₩6.2bn |
| Q4 2024 derived | ₩2.8bn | +17.9% | −₩7.8bn margin −276.1% | −₩6.4bn |
| Q3 2024 | ₩2.3bn | -0.0% | −₩6.0bn margin −266.0% | −₩5.6bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Qurient top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Qurient news Korean headlines
-
Major큐리언트, ESMO서 항암제 '모카시클립' 임상 1상 성과 발표
1 more on this story · 1 outlets
- 큐리언트 "ESMO서 모카시클립 임상 결과 발표"뉴시스경제 · Oct 26 09:43
-
Major큐리언트, ‘모카시클립’ ESMO서 1상 결과 공개…안전성·초기 항암 효능 확인
1 more on this story · 1 outlets
- 큐리언트 ‘모카시클립’, ESMO서 고형암 1상 결과 공개메디코파마 · Oct 19 09:14
-
Major큐리언트 모카시클립, ESMO 임상 1상 초록 공개
2 more on this story · 2 outlets
- 큐리언트, ESMO서 항암신약 '모카시클립' 임상 1상 결과 공개뉴스1 · Oct 19 08:39
- 큐리언트, 모카시클립 1상 초록 공개…병용 임상 개발 근거 확보메디파나뉴스 · Oct 19 08:45
-
큐리언트 ‘모카시클립’, 말기 고형암 1상서 부분관해 확인…2상 본격화
1 more on this story · 1 outlets
- 큐리언트 모카시클립, 임상 1상서 부분관해 2명 확인…2상 권장용량 확정PRESS9 · Oct 19 09:04
-
큐리언트, 론자와 ADC 플랫폼 글로벌 사업화 확대
1 more on this story · 1 outlets
- 큐리언트, 론자와 ADC 플랫폼 확장…글로벌 사업개발 본격화한스경제 · Oct 15 12:34
-
큐리언트·론자, 유럽서 이중 페이로드 ADC 플랫폼 공개
3 more on this story · 3 outlets
- 큐리언트 “론자, 이중 페이로드 ADC 플랫폼 글로벌 사업화 박차”더바이오 · Oct 15 08:52
- 큐리언트·론자, 이중 페이로드 ADC 플랫폼 유럽 시장 공략뉴스1 · Oct 15 09:01
- 큐리언트·론자, 英 ELRIG서 이중 페이로드 ADC 플랫폼 발표 "사업화 속도"머니투데이 · Oct 15 09:13